Blincyto gets positive recommendation from NICE

The National Institute for Health and Care Excellence (NICE) has published its Final Appraisal Determination (FAD) recommending Blincyto (blinatumomab) as an option for treating adults with Philadelphia-chromosome-negative (Ph-) relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL).

The decision is on the basis of the discount agreed in the patient access scheme, said the drug’s maker, US biotech giant Amgen (Nasdaq: AMGN).

The medicines cost-effectiveness watchdog reviewed the data available on the clinical and cost-effectiveness of blinatumomab. Having considered evidence on the nature of the disease and the value placed on the benefits of blinatumomab by people with the condition, those who represent them, and clinical experts, NICE concluded that it is a cost-effective use of NHS resources under the end-of-life criteria.